As of 2026-04-12, the Relative Valuation of Anavex Life Sciences Corp (AVXL) is (8.84) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.95 USD, the upside of Anavex Life Sciences Corp based on Relative Valuation is -399.6%.
The range of the Relative Valuation is (7.82) - (9.37) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.1x - 23.7x | 20.3x |
| Forward P/E multiples | 16.9x - 21.7x | 20.7x |
| Fair Price | (7.82) - (9.37) | (8.84) |
| Upside | -365.1% - -417.7% | -399.6% |
| Date | P/E |
| 2026-04-09 | -7.08 |
| 2026-04-08 | -7.05 |
| 2026-04-07 | -7.15 |
| 2026-04-06 | -6.87 |
| 2026-04-02 | -6.94 |
| 2026-04-01 | -7.19 |
| 2026-03-31 | -7.12 |
| 2026-03-30 | -6.54 |
| 2026-03-27 | -6.54 |
| 2026-03-26 | -6.68 |
| 2026-03-25 | -6.36 |
| 2026-03-24 | -9.72 |
| 2026-03-23 | -10.30 |
| 2026-03-20 | -9.42 |
| 2026-03-19 | -9.74 |
| 2026-03-18 | -9.88 |
| 2026-03-17 | -10.56 |
| 2026-03-16 | -10.93 |
| 2026-03-13 | -10.79 |
| 2026-03-12 | -10.79 |
| 2026-03-11 | -10.79 |
| 2026-03-10 | -10.76 |
| 2026-03-09 | -11.11 |
| 2026-03-06 | -10.79 |
| 2026-03-05 | -11.04 |
| 2026-03-04 | -11.60 |
| 2026-03-03 | -10.88 |
| 2026-03-02 | -10.51 |
| 2026-02-27 | -10.28 |
| 2026-02-26 | -10.35 |
| 2026-02-25 | -10.21 |
| 2026-02-24 | -10.11 |
| 2026-02-23 | -9.65 |
| 2026-02-20 | -9.56 |
| 2026-02-19 | -9.56 |
| 2026-02-18 | -9.37 |
| 2026-02-17 | -9.37 |
| 2026-02-13 | -9.12 |
| 2026-02-12 | -9.09 |
| 2026-02-11 | -9.00 |
| 2026-02-10 | -9.19 |
| 2026-02-09 | -10.09 |
| 2026-02-06 | -9.51 |
| 2026-02-05 | -8.84 |
| 2026-02-04 | -9.58 |
| 2026-02-03 | -10.18 |
| 2026-02-02 | -10.49 |
| 2026-01-30 | -10.90 |
| 2026-01-29 | -11.39 |
| 2026-01-28 | -11.30 |